These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36275650)

  • 1. Bet v 1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Bet v 1 in a murine immunogenicity model.
    van Strien J; Warmenhoven H; Logiantara A; Makurat M; Aglas L; Bethanis A; Leboux R; van Rijt L; MacKay JA; van Schijndel JW; Schneider G; Olsthoorn R; Jiskoot W; van Ree R; Kros A
    Front Immunol; 2022; 13():1006776. PubMed ID: 36275650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic liposomes bearing Bet v 1 by coiled coil-formation are hypo-allergenic and induce strong immunogenicity in mice.
    Warmenhoven H; Leboux R; Bethanis A; van Strien J; Logiantara A; van Schijndel H; Aglas L; van Rijt L; Slütter B; Kros A; Jiskoot W; van Ree R
    Front Allergy; 2022; 3():1092262. PubMed ID: 36704756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
    Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
    Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
    Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
    J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1.
    Akinfenwa O; Huang HJ; Linhart B; Focke-Tejkl M; Vrtala S; Poroshina A; Nikonova A; Khaitov M; Campion NJ; Eckl-Dorna J; Niederberger-Leppin V; Kratzer B; Tauber PA; Pickl WF; Kundi M; Campana R; Valenta R
    Front Immunol; 2021; 12():744544. PubMed ID: 34795666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins.
    Karamloo F; Schmitz N; Scheurer S; Foetisch K; Hoffmann A; Haustein D; Vieths S
    J Allergy Clin Immunol; 1999 Nov; 104(5):991-9. PubMed ID: 10550744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
    Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
    Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity.
    Kitzmüller C; Kalser J; Mutschlechner S; Hauser M; Zlabinger GJ; Ferreira F; Bohle B
    J Allergy Clin Immunol; 2018 Jan; 141(1):293-299.e6. PubMed ID: 28456624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2.
    Vrtala S; Mayer P; Ferreira F; Susani M; Sehon AH; Kraft D; Valenta R
    J Allergy Clin Immunol; 1996 Nov; 98(5 Pt 1):913-21. PubMed ID: 8939154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
    Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
    J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
    Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
    J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season.
    van Hage-Hamsten M; Kronqvist M; Zetterström O; Johansson E; Niederberger V; Vrtala S; Grönlund H; Grönneberg R; Valenta R
    J Allergy Clin Immunol; 1999 Nov; 104(5):969-77. PubMed ID: 10550741
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Aglas L; Bethanis A; Chrusciel P; Stolz F; Gruen M; Jaakkola UM; Jongejan L; Yatkin E; Van Ree R
    Front Immunol; 2020; 11():2118. PubMed ID: 33013894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1.
    Mahler V; Vrtala S; Kuss O; Diepgen TL; Suck R; Cromwell O; Fiebig H; Hartl A; Thalhamer J; Schuler G; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Jan; 34(1):115-22. PubMed ID: 14720271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal IgE antibodies against birch pollen allergens: novel tools for biological characterization and standardization of allergens.
    Kaul S; Scheurer S; Danz N; Schicktanz S; Vieths S; Hoffmann A
    J Allergy Clin Immunol; 2003 Jun; 111(6):1262-8. PubMed ID: 12789227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice.
    Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U
    PLoS One; 2012; 7(6):e39409. PubMed ID: 22768077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.
    Vrtala S; Grote M; Ferreira F; Susani M; Stocker B; Kraft D; Valenta R
    Int Arch Allergy Immunol; 1995; 107(1-3):290-4. PubMed ID: 7613152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bet v 1--a Trojan horse for small ligands boosting allergic sensitization?
    Asam C; Batista AL; Moraes AH; de Paula VS; Almeida FC; Aglas L; Kitzmüller C; Bohle B; Ebner C; Ferreira F; Wallner M; Valente AP
    Clin Exp Allergy; 2014 Aug; 44(8):1083-93. PubMed ID: 24979350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.